|
COPYRIGHT 2004 Asia Pulse Pty Ltd
(Full text of a statement. Contact details below.)
BASEL, Oct 22 /PRNewswire-AsiaNet/ - Roche announced today that its innovative cancer drug, Avastin has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP).
The CHMP has recommended that Avastin (bevacizumab) in combination with intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.
The CHMP's positive recommendation will now be proposed for final marketing approval by the European Commission. The recommendation is based on data from a pivotal Phase III study that showed that patients treated with Avastin plus chemotherapy* lived on average 30 per cent longer than patients receiving chemotherapy alone (20.3 months versus 15.6 months)(1). Also, on average the addition of Avastin increased by 71 per cent the amount of time that patients were without disease progression, compared to patients receiving chemotherapy...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
